PureTech Health (PRTC) noted that its founded entity, Seaport Therapeutics, announced that the first participant has been dosed in the Phase 1 study of GlyphAgo.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTC:
- Buy Rating for PureTech Health Driven by Promising LYT-100 Developments and Strategic Initiatives
- PureTech Health Reports Strong Progress and Financial Stability
- PureTech says Vedanta ulcerative colitis study missed endpoint
- PureTech falls 7% to $16.19 after founded entity study miss
- DiaMedica Therapeutics CMO Lorianne Masuoka resigns, Julie Krop succeeds